United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia,

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 1326mg equivalent to 1000 mg methylprednisolone;   - powder for injection - 1000 mg - active: methylprednisolone sodium succinate 1326mg equivalent to 1000 mg methylprednisolone   excipient: dibasic sodium phosphate monobasic sodium phosphate

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - methylprednisolone sodium succinate (unii: lec9gky20k) (methylprednisolone - unii:x4w7zr7023) - when oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, usp, is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (diamond-blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. for the palliative management of leukemias and lymphomas. acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. methylprednisolone sodium succinate sterile powder is contraindicated: - in systemic fungal infections and patients with known hypersensitivity to the product and its constituents; - for intrathecal administration. reports of severe medical events have been associated with this route of administration. intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. the use of methylprednisolone sodium succinate for injection is contraindicated in premature infants because when reconstituted will contain benzyl alcohol. (see warnings  and precautions: pediatric use)

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - methylprednisolone as sodium succinate - powder for solution for inj/inf - methylprednisolone as sodium succinate 62.5 mg/ml - methylprednisolone - methylprednisolone - solu medrol is indicated to treat any condition in which im or iv corticosteroid treatment is required such as: endocrine disorders, rheumatic disorders, collagen diseases, immune complex diseases, dermatologic diseases, allergic states, ophthalmic diseases, gastrointestinal diseases, respiratory diseases, hematologic disorders, management of neoplastic diseases, edematous states, nervous system disorders and organ transplantation.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - methylprednisolone sodium succinate - powder and solvent for solution for injection - 1000 mg - methylprednisolone 62.5 mg/ml - methylprednisolone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - methylprednisolone sodium succinate - eq. methylprednisolone 1000 mg - powder and solvent for solution for injection - 1000 mg - methylprednisolone sodium succinate - methylprednisolone

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer, belgium - methylprednisolone - powder, for solution - 1000 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - methylprednisolone sodium succinate - powder for solution for injection - 1000 mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

orion corporation - methylprednisolone (methylprednisolone sodium succinate) - powder for solution for injection - 1000mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - methylprednisolone sodium succinate - powder and solvent for solution for injection - 500mg